ArticleCureus2026
Metastatic Uterine Sarcomas: A Retrospective Analysis on Clinical Outcomes and Biology.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Metastatic uterine sarcomas are aggressive malignancies with poor outcomes and a scarcity of real-world data. Methods This retrospective study collected data from patients treated over eight years, from January 2018 to December 2025. The included patients had histopathologically confirmed sarcoma arising from the uterus who were deemed unresectable or were metastatic and treated with palliative intent. Results Twenty-eight patients were included in the final analysis, and 23 received first-line treatment. High-grade endometrial stromal sarcomas (HG-ESS) and uterine leiomyosarcomas (ULMS) were the most common histologies. The most common metastatic sites were the pelvis/peritoneum (60.7%) and lungs (57.1%). Anthracycline-based regimens, with or without ifosfamide and gemcitabine, plus docetaxel, were the most common first-line regimens. Disease control rate (DCR) was 13/23 (56.52%). Overall survival (OS) for the whole cohort was five months (95% confidence interval (CI): 0.8-9.2 months). By histologic subtype, HG-ESS had the shortest median OS at four months (95% CI: 1.84-6.12 months), whereas ULMS had the best prognosis, with a median OS of 11 months (95% CI: 2.35-19.65 months). Patients on best supportive care had a median OS of one month, whereas those receiving any treatment had a median OS of 10 months (95% CI: 5.9-14 months) (p<0.001). Patients with a maximum tumor dimension of less than 10 cm had significantly better OS than those with more than 10 cm (10 months (95% CI: 4.8-15.2 months) versus five months (95% CI: 2.6-7.4 months); p=0.031). Conclusion The prognosis of metastatic uterine sarcomas remains dismal. Further studies are needed to identify the optimal treatment and sequencing while incorporating molecular classification, especially for HG-ESS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.